Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIA: TEDOPI versus docetaxel in metastatic NSCLC after immune checkpoint inhibitor failure
2023-509340-10-00Phase 3Authorised
- Sponsor
- OSE Immunotherapeutics
- Start
- Oct 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing TEDOPI with docetaxel (2 arms). Primary endpoint: Overall survival. Planned start Oct 2024; status: authorised.
02
Drugs
Tedopidocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509340-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509340-10-00.